Šalis: Didžioji Britanija
kalba: anglų
Šaltinis: MHRA (Medicines & Healthcare Products Regulatory Agency)
Carvedilol
DE Pharmaceuticals
C07AG02
Carvedilol
12.5mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02040000
A NN EXU RE- 1 (Ref. SOP. No.: DFD080) ART WORK APPR OVAL FORM _R_ _elon_ _@hem _ PATIENT INFORMATION LEAFLET: lnfonnatfon for the user CARVEDI LOL 3.125 mg, 6.25 mg, 12.5 mg & 25 mg TABL ETS Read 111 of this feaRet carefully before you atart taking this medicine btcause h contains Important I nformation f or yo u. Keep thi s leal1el. You may need to read It again. If you have further questions. please ask )'OUr dod.ororyour pharmaci st This medicine has been presttibed for you only. Do nol pas.sit on to olhers; it may harm them, eve n if their symptoms are the same as youwhich Is being tr ei Hed by medicines glven In to your 11 etns (lntrav Perskaitykite visą dokumentą
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Carvedilol 12.5 mg Tablets SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 12.5 mg of Carvedilol Excipient(s) with known effect: Each tablet contains 62.94 mg of lactose For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet Carvedilol Tablets are cream coloured, circular, biconvex tablets, 8.30 mm-8.70 mm in diameter, marked ‘C12’ on one face and plain on the reverse face. SUMMARY OF PRODUCT CHARACTERISTICS 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Essential hypertension Chronic stable angina pectoris Adjunctive treatment of moderate to severe stable chronic heart failure. SUMMARY OF PRODUCT CHARACTERISTICS 4 CLINICAL PARTICULARS 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology ESSENTIAL HYPERTENSION Carvedilol may be used for the treatment of hypertension alone or in combination with other antihypertensives, especially thiazide diuretics. Once daily dosing is recommended, however the recommended maximum single dose is 25 mg and the recommended maximum daily dose is 50 mg. _ _ _Adults:_ The recommended initial dose is 12.5 mg once a day for the first two days. Thereafter the treatment is continued at the dose 25 mg/day. If necessary, the dose may be further increased gradually at intervals of two weeks or more rarely. _Elderly:_ The recommended initial dose in hypertension is 12.5 mg once a day which may also be sufficient for continued treatment. However, if the therapeutic response is inadequate at this dose, the dose may be further increased gradually at intervals of two weeks or more rarely. CHRONIC STABLE ANGINA PECTORIS: A twice-daily regimen is recommended. _Adults:_ The recommended initial dosage is 12.5 mg twice a day for the first two days. Thereafter, the treatment is continued at the dose 25 mg twice a day. If necessary, the dose may be further increased gradually at intervals of two weeks or more rarely to the recommended maximum dose of 100 mg Perskaitykite visą dokumentą